News from imprimis pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 16, 2014, 08:00 ET

Imprimis Pharmaceuticals' Dropless Formulations to be Presented in Multiple Sessions at the 2014 American Academy of Ophthalmology (AAO) Meeting

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of high...

Sep 16, 2014, 08:00 ET

Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to delivering high quality and novel medicines to...

Sep 08, 2014, 08:00 ET

Imprimis Pharmaceuticals Appoints Healthcare Leader William H. Nelson to its Board of Directors

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to delivering high quality and novel medicines to...

Aug 13, 2014, 16:30 ET

Imprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable...

Jul 24, 2014, 08:00 ET

Imprimis Pharmaceuticals' Go Dropless™ Cataract Surgery Formulations to be Featured in Two Sessions at the 2014 American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and...

Jun 24, 2014, 08:00 ET

Imprimis Pharmaceuticals Go Dropless™ Video Interview Survey Reveals 95% of Leading Cataract Surgeons Surveyed Would Prefer Dropless Therapy

 Imprimis Pharmaceuticals, Inc. (Nasdaq:IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality,...

May 28, 2014, 08:00 ET

Imprimis Pharmaceuticals to Exhibit Go Dropless™ Cataract Surgery Formulations at 2014 Kiawah Eye Meeting

 Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality,...

Apr 22, 2014, 08:00 ET

Imprimis Pharmaceuticals' Go Dropless™ Cataract Surgery Formulations to be Presented in Two Sessions at the 2014 American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium & Congress

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and...

Mar 25, 2014, 06:00 ET

Imprimis Pharmaceuticals Scheduled to Present at 13th Annual Needham Healthcare Conference

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary...

Mar 04, 2014, 06:00 ET

Imprimis Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

 Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of...

Feb 25, 2014, 06:00 ET

Imprimis Pharmaceuticals' Pre-Commercial Ophthalmic Formulations to be Presented at 2014 American-European Congress of Ophthalmic Surgery (ACOS™)/Dulaney Winter Meeting

 Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of...

Feb 19, 2014, 06:00 ET

Imprimis Pharmaceuticals Names Pharmacy Business Leader Randle House as Vice President of Pharmacy Operations

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary...

Feb 11, 2014, 06:00 ET

Imprimis Pharmaceuticals Announces Acquisition of Pharmacy Creations, Empowering Company to Make and Distribute its Patent-Pending Proprietary Formulations

 Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of...

Jan 28, 2014, 06:00 ET

Imprimis Pharmaceuticals to Exhibit Pre-Commercial Ophthalmic Formulations At 2014 ACES/SEE Caribbean Eye Meeting

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary...

Dec 09, 2013, 08:00 ET

Imprimis Pharmaceuticals Announces Plans to Pursue Compounding Pharmacy Strategy in Accordance with the Recently Passed Drug Quality and Security Act

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a pharmaceutical company focused on commercial development of novel drug formulations and drug...

Nov 19, 2013, 08:00 ET

Imprimis Optimistic After Congressional Passage of the Drug Quality and Security Act

 Imprimis Pharmaceuticals, Inc. (IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and...

Nov 12, 2013, 08:00 ET

Imprimis Pharmaceutical Names Seasoned Ophthalmology Executive John Saharek as Vice-President of Commercialization for its Ophthalmology Division

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians...

Nov 08, 2013, 13:36 ET

Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by...

Nov 06, 2013, 08:00 ET

Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians...

Aug 28, 2013, 08:00 ET

Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which is focused on the commercialization of drug formulations through a growing proprietary network...